---
title: "ImmuCell CEO Paul te Boekhorst buys 8,000 shares for $75,960"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290436973.md"
description: "ImmuCell CEO Paul te Boekhorst purchased 8,000 common shares at $9.50 each, totaling $75,960. This transaction increased his direct stake in the company to 17,785 shares."
datetime: "2026-06-22T12:34:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290436973.md)
  - [en](https://longbridge.com/en/news/290436973.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290436973.md)
---

# ImmuCell CEO Paul te Boekhorst buys 8,000 shares for $75,960

-   ImmuCell President and CEO Paul Francis Olivier te Boekhorst bought 8,000 common shares at USD 9.5 each. \* His direct stake rose to 17,785 shares following the purchase. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmuCell Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-021258), on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ICCC.US](https://longbridge.com/en/quote/ICCC.US.md)

## Related News & Research

- [Immucell CEO Makes Bold Move With Significant Personal Stock Purchase](https://longbridge.com/en/news/290501560.md)
- [Werner Enterprises director Paul A. Hoelting files initial beneficial ownership statement](https://longbridge.com/en/news/295443808.md)
- [Viavi EVP and Chief Marketing & Strategy Officer Paul McNab sells 1,595 shares worth $59,593.15](https://longbridge.com/en/news/295535658.md)
- [Everus Construction VP, CLO & Corporate Secretary Paul R. Sanderson lepas 3.300 saham senilai $451.077,33](https://longbridge.com/en/news/295564090.md)
- [Pennant Group Chief Clinical Officer Jason Paul Steik sells 1,394 shares for $53,700.67](https://longbridge.com/en/news/295442543.md)